If ACD680 were to reach the market, it would deepen Lilly’s Alzheimer’s legacy past anti-amyloid-beta therapy, Kisunla.
Amyloid is increasingly ceding ground in Alzheimer’s disease R&D to new approaches targeting inflammation, immune processes, ...
Blood-based biomarkers may help characterize amyloid and tau burden in patients with subjective cognitive decline and mild cognitive impairment.
Findings show lower amyloid PET positivity in Black and Latinx adults with cognitive impairment, highlighting disparities in ...
Morning Overview on MSN
Indiana University researchers just identified an enzyme called IDOL inside neurons — yanking it out cleared amyloid plaques and shielded brain cells from Alzheimer dam…
A team at Indiana University School of Medicine’s Stark Neurosciences Research Center has published findings showing that ...
A recent study led by a team of researchers at The Johns Hopkins University School of Medicine examining aging mice has provided what is believed to be the first evidence that amyloid beta ...
Critics of the amyloid hypothesis point out that some people with brain amyloid are cognitively fine, thank you very much. Indeed, variability in plaque burden among cognitively normal older people, ...
Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results